

**For Immediate Release**  
**Alembic Pharmaceuticals Limited**  
**Consolidated Results for Quarter ended 30.06.2014**

**Revenues up by 16% at Rs 496 crores**  
**PBT up by 40% at Rs 85 crores**

**Editors Synopsis**

**Quarter ended 30th June 2014**

- **Net sales up by 16% to Rs 496.1 crores against Rs 428.8 crores in the corresponding quarter last year**
- **Profit before tax up by 40% to Rs 84.9 crores against Rs 60.5 crores in the corresponding quarter last year**
- **Net profit after tax up by 39% to Rs 64.7 crores against Rs 46.6 crores in the corresponding quarter last year**
- **EBITDA margins is 19.5% at Rs 96.7 crores against 16.7% at Rs 71.5 crores in the corresponding quarter last year**
- **Domestic Branded formulations sales up 16% for the quarter at Rs. 223.3 crores against Rs. 192.0 crores in corresponding quarter last year.**
- **International Generic Formulations sales up 33% for the quarter at Rs. 113.8 crores against Rs. 85.5 crores in corresponding quarter last year**
- **3 ANDA application were filed for the quarter taking cumulative ANDA filings of the Company to 64**
- **3 ANDA approvals were received for the quarter taking cumulative ANDA/NDA approvals to 35 (including 5 tentative approvals)**

**Vadodara, 28<sup>th</sup> July, 2014**

Alembic Pharmaceuticals Limited reported a 16% increase in revenues to Rs 496.1 crores for the quarter ended 30<sup>th</sup> June 2014, compared to Rs 428.8 crores in the corresponding quarter last year.

The Company posted 40% growth in profit before tax at Rs. 84.9 crores for the quarter ended 30<sup>th</sup> June 2014 against Rs 60.5 crores posted in corresponding quarter last fiscal.

The net profit grew by 39% at Rs 64.7 crores for the quarter ended 30<sup>th</sup> June 2014 against Rs 46.6 crores in corresponding quarter last fiscal.

EBIDTA margins for quarter ended 30<sup>th</sup> June 2014 up at 19.5% to Rs 96.7 crores from 16.7% at Rs 71.5 crores for corresponding quarter last year.

### **India Branded Formulations Business**

The India Branded formulations business posted sales of Rs. 223.3 crores against Rs. 192.0 crores with a 16% growth over the corresponding quarter of the previous year.

Specialty and Acute segments grew by 25% and 4% respectively in current quarter.

### **International Generics**

International Generic Formulation posted growth of 33% and posted sales of Rs. 113.8 crores against Rs. 85.5 crores over the corresponding quarter last year.

During the quarter 3 ANDA applications were filed taking cumulative ANDA filings of the Company to 64. During the quarter 3 ANDA approvals were received taking cumulative ANDA/NDA approvals to 35 (including 5 tentative approvals).

Summary of Total Revenue is as under:

(Rs. in Lacs)

Particulars	Q1 FY15	Q1 FY14	% Change
<b>Formulation</b>			
India Branded	22328	19197	16%
India Generics	2522	2645	(-) 5%
International Branded	2268	1501	51%
International Generics	11381	8547	33%
<b>API</b>	10631	10697	(-) 1%
<b>Export Incentives</b>	483	290	-
<b>Total</b>	<b>49613</b>	<b>42877</b>	<b>16%</b>

The Profit break-up is as under:

(Rs. in Lacs)

Particulars	Q1 FY15	Q1 FY14	% Change
Operating Income	9667	7148	35%
Profit Before Tax	8493	6050	40%
Net Profit after Tax	6467	4664	39%

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities all over the world including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a marketing team of over 4400 are well recognized by doctors and patients.

Information about the company can be found at [www.alembic-india.com](http://www.alembic-india.com); (reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

**For more information contact:**

**Alembic Pharmaceuticals Limited**

**Ajay Kumar Desai**

**Phone: +91 22 – 306 11681**

**Email: [ajay.desai@alembic.co.in](mailto:ajay.desai@alembic.co.in)**

**Mitanshu Shah**

**Phone: +91 265 – 3007630**

**Email: [mitanshu.shah@alembic.co.in](mailto:mitanshu.shah@alembic.co.in)**